Maze X is an acceleration program of social impact, which aims at supporting hard-working founders who have the grit to test new ideas and aim for innovative outcomes.
This program is promoted by the Calouste Gulbenkian and the Edmond de Rothschild Foundations and the company MAZE, with PLMJ and BNP Paribas joining as corporate member, and Hospital da Luz Learning Health, Casa do Impacto as partners.
In the 2021 edition, Maze X selected ten European start-ups, of which three are Portuguese. CBR Genomics is proud of being one of these three.
Over four months, we will be working together to foster the impact of using genomic data in healthcare management.
We are very excited to be part of this cohort. Through the creation of these synergies, we’ll be a step closer to bring Genomics to the daily clinical practice, improving clinical outcomes and impacting personalised healthcare.